Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated ...

Plan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025 Expect data readouts for DISC-0974 program in H2 2025, including initial results of Phase 2 anemia of myelofibrosis (MF ...

Disc Medicine anticipates NDA submission for bitopertin in EPP by late 2025, while progressing multiple clinical trials and maintaining financial strength. Disc Medicine, Inc. announced its plans to ...

FDA is slated to decide on Disc Medicine's Bitopertin by February. ・Approval for Lilly’s obesity pill is expected by April 10 ...